"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
Mechanism of Action
CroFab (crotalidae polyvalent immune fab ovine) is a venom-specific Fab fragment of immunoglobulin G (IgG) that works by binding and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body.
CroFab (crotalidae polyvalent immune fab ovine) was effective in neutralizing the venoms of 10 clinically important North American crotalid snakes in a murine lethality model (see Table 2) . In addition, preliminary data from experiments in mice using whole IgG from the sheep immunized for CroFab (crotalidae polyvalent immune fab ovine) production suggest that CroFab (crotalidae polyvalent immune fab ovine) might possess antigenic cross-reactivity against the venoms of some Middle Eastern and North African snakes, however, there are no clinical data available to confirm these findings.
Table 2. ED50 Values for CroFab (crotalidae polyvalent immune fab ovine) in Mice
|Study Objective & Design||Endpoint Measured||Major Findings and Conclusions|
|To determine the cross-neutralizing ability
of CroFab (crotalidae polyvalent immune fab ovine) to protect mice from the lethal effects of venom from clinically
Separate groups of mice were injected with increasing doses of CroFab (crotalidae polyvalent immune fab ovine) pre-mixed with two LD50 of each venom tested.
|ED50 for each venom||(Note: Lower numbers represent increased potency against venoms listed)|
|Challenge Venom||ED50 (expressed as mg antivenin/mg venom)|
|C. h. atricaudatus||7|
|C. v. helleri||122|
|C. m. molossus||25|
|A. c. contortrix||4|
|S. m. barbouri||7|
|C. h. horridus||6|
|Based on the data from this study in mice, CroFab (crotalidae polyvalent immune fab ovine) has relatively good crossprotection against venoms not used in the immunization of flocks used to produce it, except for C. v. helleri, where a very high dose is required, and for C. m. molossus, where a moderately high dose is required.|
The planned pharmacokinetic study of CroFab (crotalidae polyvalent immune fab ovine) was not adequately performed. A limited number of samples were collected from three patients. Based on these data, estimates of elimination half-life were made. The elimination half-life for total Fab ranged from approximately 12 to 23 hours. These limited pharmacokinetic estimates of half-life are augmented by data obtained with an analogous ovine Fab product produced by Protherics Inc. using a similar production process. In that study, 8 healthy subjects were given 1 mg of intravenous digoxin followed by an approximately equimolar neutralizing dose of 76 mg of digoxin immune Fab (ovine). Total Fab was shown to have a volume of distribution of 0.3 L/kg, a systemic clearance of 32 mL/min (approximately 0.4 mL/min/kg) and an elimination half-life of approximately 15 hours.
No clinical studies have been conducted comparing CroFab (crotalidae polyvalent immune fab ovine) with other antivenins, therefore, no comparisons can be made between CroFab (crotalidae polyvalent immune fab ovine) and other antivenins.
Two clinical trials using CroFab (crotalidae polyvalent immune fab ovine) have been conducted. They were prospectively defined, open-label, multi-center trials conducted in otherwise healthy patients 11 years of age or older who had suffered from minimal or moderate (as defined in Table 3) North American crotalid envenomation that showed evidence of progression. Progression was defined as the worsening of any evaluation parameter used in the grading of an envenomation: local injury, laboratory abnormality or symptoms and signs attributable to crotalid snake venom poisoning. Both clinical trials excluded patients with Copperhead envenomation. To date, there are no clinical data supporting the efficacy of CroFab (crotalidae polyvalent immune fab ovine) in patients presenting with severe envenomation.
Table 3. Definition of Minimal, Moderate, and Severe Envenomation
in Clinical Studies of CroFab (crotalidae polyvalent immune fab ovine)
|Minimal||Swelling, pain, and ecchymosis limited to the immediate bite
Systemic signs and symptoms absent;
Coagulation parameters normal with no clinical evidence of bleeding.
|Moderate||Swelling, pain, and ecchymosis involving less than a full extremity
or, if bite was sustained on the trunk, head or neck, extending less than
Systemic signs and symptoms may be present but not life threatening, including but not limited to nausea, vomiting, oral paresthesia or unusual tastes, mild hypotension (systolic blood pressure >90 mmHg), mild tachycardia (heart rate <150), and tachypnea;
Coagulation parameters may be abnormal, but no clinical evidence of bleeding present. Minor hematuria, gum bleeding and nosebleeds are allowed if they are not considered severe in the investigators judgment.
|Severe||Swelling, pain, and ecchymosis involving more than an entire
extremity or threatening the airway;
Systemic signs and symptoms are markedly abnormal, including severe alteration of mental status, severe hypotension, severe tachycardia, tachypnea, or respiratory insufficiency;
Coagulation parameters are abnormal, with serious bleeding or severe threat of bleeding.
In both clinical studies, efficacy was determined using a Snakebite Severity Score (SSS)  (referred to as the efficacy score or ES in these clinical studies) and an investigator's clinical assessment (ICA) of efficacy. The SSS (referred to as the ES) is a tool used to measure the severity of envenomation based on six body categories: local wound (e.g., pain, swelling and ecchymosis), pulmonary, cardiovascular, gastrointestinal, hematological, and nervous system effects. A higher score indicates worse symptoms. In a retrospective study using medical records of 108 snakebite victims , the SSS has been shown to correlate well with physicians' assessment of the patient's condition at presentation (Pearson correlation coefficient: r=0.63, p<0.0001) and when the patient's condition was at its worst (r=0.70, p<0.0001). In this study, the condition of 87/108 patients worsened during hospitalization. Changes in the physicians' assessment of condition correlated well with changes in SSS. CroFab (crotalidae polyvalent immune fab ovine) was required to prevent an increase in the ES in order to demonstrate efficacy.
The ICA was based on the investigator's clinical judgment as to whether the patient had a:
- Clinical response (pre-treatment signs and symptoms of envenomation were arrested or improved after treatment)
- Partial response (signs and symptoms of envenomation worsened, but at a slower rate than expected after treatment)
- Non-response (the patient's condition was not favorably affected by the treatment).
Safety was assessed by monitoring for early allergic events, such as anaphylaxis and early serum reactions during CroFab (crotalidae polyvalent immune fab ovine) infusion, and late events, such as late serum reactions.
In the first clinical study of CroFab (crotalidae polyvalent immune fab ovine) , 11 patients received an intravenous dose of 4 vials of CroFab (crotalidae polyvalent immune fab ovine) over 60 minutes. An additional 4-vial dose of CroFab (crotalidae polyvalent immune fab ovine) was administered after completion of the first CroFab (crotalidae polyvalent immune fab ovine) infusion, if deemed necessary by the investigator. At the 1-hour assessment, 10 out of 11 patients had no change or a decrease in their ES. Ten of 11 patients were also judged to have a clinical response by the ICA. Several patients, after initial clinical response, subsequently required additional vials of CroFab (crotalidae polyvalent immune fab ovine) to stem progressive or recurrent symptoms and signs. No patient in this first study experienced an anaphylactic or anaphylactoid response or evidence of an early or late serum reaction as a result of administration of CroFab (crotalidae polyvalent immune fab ovine) .
Based on observations from the first study, the second clinical study of CroFab (crotalidae polyvalent immune fab ovine) compared two different dosage schedules. Patients were given an initial intravenous dose of 6 vials of CroFab (crotalidae polyvalent immune fab ovine) with an option to retreat with an additional 6 vials, if needed, to achieve initial control of the envenomation syndrome. Initial control was defined as complete arrest of local manifestations, and return of coagulation tests and systemic signs to normal. Once initial control was achieved, patients were randomized to receive additional CroFab (crotalidae polyvalent immune fab ovine) either every 6 hours for 18 hours (Scheduled Group) or as needed (PRN Group).
In this trial, CroFab (crotalidae polyvalent immune fab ovine) was administered safely to 31 patients with minimal or moderate crotalid envenomation. All 31 patients enrolled in the study achieved initial control of their envenomation with CroFab (crotalidae polyvalent immune fab ovine) , and 30, 25 and 26 of the 31 patients achieved a clinical response based on the ICA at 1, 6 and 12 hours respectively following initial control. Additionally, the mean ES was significantly decreased across the patient groups by the 12-hour evaluation time point (p=0.05 for the Scheduled Group; p=0.05 for the PRN Group) (see Table 4). There was no statistically significant difference between the Scheduled Group and the PRN Group with regard to the decrease in ES.
Table 4. Summary of Patient Efficacy Scores for Scheduled
and PRN Groups
|Time Period||Scheduled Group (n=15)
Mean ± SD
|PRN Group (n=16)
Mean ± SD
|Baseline||4.0 ± 1.3||4.7 ± 2.5|
|End of Initial Control Antivenin Infusion(s)||3.2 ± 1.4||3.3 ± 1.3|
|1 hour after Initial Control achieved||3.1 ± 1.3||3.2 ± 0.9|
|6 hours after Initial Control achieved||2.6 ± 1.5||2.6 ± 1.3|
|12 hours after Initial Control achieved||2.4 ± 1.1**||2.4 ± 1.2**|
|*No change or a decline in the Efficacy Score was considered
an indication of clinical response and a sign of efficacy.
**For both the Scheduled and the PRN Groups, differences in the Efficacy Score at the four post-baseline assessment times were statistically decreased from baseline by Friedman's test (p < 0.001).
In published literature accounts of rattlesnake bites, it has been noted that a decrease in platelets can accompany moderately severe envenomation, which whole blood transfusions could not correct . These platelet count decreases have been observed to last for many hours and often several days following the venomous bite [3, 4, 5]. In this clinical study, 6 patients had pre-dosing platelet counts below 100,000/mm3 (baseline average of 44,000/mm3). Of note, the platelet counts for all 6 patients increased to normal levels (average 209,000/ mm3) at 1 hour following initial control dosing with CroFab (crotalidae polyvalent immune fab ovine) (see Figure 1).
Figure 1. Graph of Platelet Counts from Baseline to 36 Hours
for Patients with Counts <100,000/mm3 at Baseline (Study TAb002)
Although there was no significant difference in the decrease in ES between the two treatment groups, the data suggest that Scheduled dosing may provide better control of envenomation symptoms caused by the continued leaking of venom from depot sites. Scheduled patients experienced a lower incidence of coagulation abnormalities at follow-up compared with PRN patients (see Table 5 and Figure 2). In addition, the need to administer additional CroFab (crotalidae polyvalent immune fab ovine) to patients in the PRN Group after initial control suggests that there is a continued need for antivenin for adequate treatment.
Table 5. Lower Incidence of Recurrence of Coagulopathies
at Follow-Up in Scheduled and PRN Dosing Groups
|Scheduled Group (n=14)*
(percent of patients with abnormal values)^
|PRN Group (n=16)
(percent of patients with abnormal values)^
|Platelet||2/14 (14%)**||9/16 (56%)**|
|Fibrinogen||2/14 (14%)||7/16 (44%)|
|^Numbers are expressed as percent of patients that
had a follow-up platelet count that was less than the count at hospital
discharge, or a fibrinogen level less than 50% of the level at hospital
*Follow-up data not available for one patient.
**Statistically significant difference, p=0.04 by Fisher's Exact test.
Figure 2. Change in Platelet Counts in Individual Patients
between Follow-Up Visits and Discharge
Patients in the Scheduled and PRN Groups are plotted separately. More patients in the PRN Group showed a reduction in platelet count after discharge than in the Scheduled Group. Only patients showing a reduced platelet count after discharge are shown.
1. Consroe P, Egen NB, Russell FE, Gerrish K, Smith DC, Sidki A, et al. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. J Trop Med Hyg 1995; 53(5):507-510.
2. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of Crotalid snakebite. Ann Emerg Med 1996; 27(3):321-326.
3. La Grange RG and Russell FE. Blood platelet studies in man and rabbits following Crotalus envenomation. Proc West Pharmacol Soc 1970;13:99-105.
4. Lyons WJ. Profound thrombocytopenia associated with Crotalus ruber ruber envenomation: a clinical case. Toxicon 1971; 9:237-240.
5. Tallon RW, Koch KL, Barnes SG, Ballard JO. Letter to Editor. N Engl J Med 1981;305:1347.
Last reviewed on RxList: 9/11/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Crofab Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.